Merus (NASDAQ:MRUS) is one of the most promising stocks according to Wall Street analysts. The 2025 Annual Meeting of the American Society of Clinical Oncology/ASCO, held in Chicago, the US, from ...

Ian Tannock on the Dangers of Poorly Designed Adjuvant CDK4/6 Clinical Trials – For example, monarchE and NATALEE did not meet the burden of proof, he and his colleagues argue ...

ASCO 2025 has been a really busy meeting for breast cancer. We've seen data from SERENA-6, which has offered an intriguing and interesting way for us to be thinking about whether we've achieved ...

Valve has announced an upcoming Team Fortress 2 update as only Valve can. A new blog post begins: "Thirteen years ago, we launched Mann vs. Machine, a chilling cautionary tale where an artificial ...

Lymphoma highlights from ASCO 2025 include data on CAR-T cell therapy, zilovertamab vedotin in relapsed or refractory (R/R) LBCL, and optimal dosing of AFM13 plus AlloNK in R/R Hodgkin lymphoma.

Software Virtual Reality & Augmented Reality Should Meta be worried? The Valve Deckard VR headset is shaping up to be a beast – here are 5 things we know Features By Hamish Hector published June ...

Brian P. Mulherin, MD, shares his key takeaways from the 2025 ASCO Annual Meeting, highlighting significant advancements in SCLC and the challenge of information overload at large conferences.

Join STAT reporters for a virtual recap of ASCO 2025 — highlighting the latest breakthroughs, industry news, and key moments from this year’s event.

Immix Biopharma today presented results at ASCO from its U.S. multi-center NEXICART-2 Phase 1/2 clinical trial of NXC-201, meeting its primary endpoint.

2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Date of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from Phase 1 Clinical Studies in Advanced ...

On ASCO Day 3, AstraZeneca is dominant (again), Protagonist Therapeutics and Takeda review blood cancer data, and more.

Kite Pharma’s bicistronic CAR T-cell therapy hit the main goal of a phase 1a trial, with zero dose-limiting toxicities (DLTs) occurring in patients with advanced B-cell lymphoma (BCL). The the ...